Mydriasis due to self-administered inhaled ipratropium bromide

Related Experiment Video

Updated: Oct 1, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

David W Bond, Harish Vyas, Helen E Venning

    European Journal of Pediatrics
    |May 10, 2002
    PubMed

    Insights

    Mydriasis, or dilated pupils, can occur from ipratropium bromide, a common asthma medication. Healthcare providers should consider this side effect, especially in young children who might misuse inhalers, if they show unusual neurological symptoms.

    Area of Science:

    • Pharmacology
    • Pediatrics
    • Ophthalmology

    Background:

    • Ipratropium bromide is a widely used bronchodilator for asthma management.
    • Mydriasis (pupil dilation) is a known, albeit uncommon, side effect of ipratropium bromide.
    • Children, even as young as 4, may self-administer asthma inhalers, presenting a risk for accidental overdose or misuse.

    Discussion:

    • Accidental or intentional self-administration of ipratropium bromide inhalers by young children can lead to systemic absorption.
    • Mydriasis can be an indicator of ipratropium bromide exposure in pediatric patients.
    • The neurological signs associated with mydriasis in this context warrant careful clinical evaluation.

    Key Insights:

    • Mydriasis is a potential adverse effect of ipratropium bromide, particularly relevant in pediatric asthma patients.
    • The risk of ipratropium bromide misuse or accidental self-administration by young children necessitates clinical awareness.
    • Abnormal neurological signs in a child with asthma may indicate ipratropium bromide-induced mydriasis.

    Outlook:

    • Further investigation into the prevalence and clinical significance of ipratropium bromide-induced mydriasis in children is warranted.
    • Educational initiatives for parents and caregivers regarding safe inhaler use in pediatric asthma are crucial.
    • Enhanced monitoring protocols for pediatric asthma patients using ipratropium bromide may be beneficial.

    More Related Videos

    Intratracheal Administration of Dry Powder Formulation in Mice07:55

    Intratracheal Administration of Dry Powder Formulation in Mice

    Published on: July 25, 2020

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung07:10

    Direct Intrabronchial Administration to Improve the Selective Agent Deposition Within the Mouse Lung

    Published on: May 20, 2019

    Related Concept Videos

    Inhaled Medications01:23

    Inhaled Medications

    Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
    Cholinergic Antagonists: Pharmacokinetics01:24

    Cholinergic Antagonists: Pharmacokinetics

    Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
    Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

    Antiasthma Drugs: Muscarinic Receptor Antagonists

    Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
    Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
    Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

    Direct-Acting Cholinergic Agonists: Therapeutic Uses

    Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
    Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

    Antiasthma Drugs: β2-Adrenoceptor Agonists

    Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
    One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
    Asthma-IV: Diagnostic and Management01:30

    Asthma-IV: Diagnostic and Management

    The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
    Clinical Assessment for Asthma:
    This is the first step in diagnosing and managing asthma. It includes: